Blockade of CD73 delays glioblastoma growth by modulating the immune environment.

Immunotherapy as an approach for cancer treatment is clinically promising. CD73, which is the enzyme that produces extracellular adenosine, favors cancer progression and protects the tumor from immune surveillance. While CD73 has recently been demonstrated to be a potential target for glioma treatment, its role in regulating the inflammatory tumor microenvironment has not yet been investigated. Thus, this study explores the immunotherapeutic value of the CD73 blockade in glioblastoma. The immuno-therapeutic value of the CD73 blockade was evaluated in vivo in immunocompetent pre-clinical glioblastoma model. As such, glioblastoma-bearing rats were nasally treated for 15 days with a siRNA CD73-loaded cationic-nanoemulsion (NE-siRNA CD73R). Apoptosis was determined by flow cytometry using Annexin-V staining and cell proliferation was analyzed by Ki67 expression by immunohistochemistry. The frequencies of the CD4+, CD8+, and CD4+CD25highCD39+ (Treg) T lymphocytes; CD11b+CD45high macrophages; CD11b+CD45low-microglia; and CD206+-M2-like phenotypes, along with expression levels of CD39 and CD73 in tumor and tumor-associated immune cells, were determined using flow cytometry, while inflammatory markers associated with tumor progression were evaluated using RT-qPCR. The CD73 blockade by NE-siRNA CD73 was found to induce tumor cell apoptosis. Meanwhile, the population of Tregs, microglia, and macrophages was significantly reduced in the tumor microenvironment, though IL-6, CCL17, and CCL22 increased. The treatment selectively decreased CD73 expression in the GB cells as well as in the tumor-associated-macrophages/microglia. This study indicates that CD73 knockdown using a nanotechnological approach to perform nasal delivery of siRNA-CD73 to CNS can potentially regulate the glioblastoma immune microenvironment and delay tumor growth by inducing apoptosis.

CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model.

Glioblastoma is the most devastating primary brain tumor and effective therapies are not available. Treatment is based on surgery followed by radio and chemotherapy with temozolomide (TMZ), but TMZ increases patient survival only by 2 months. CD73, an enzyme responsible for adenosine production, emerges as a target for glioblastoma treatment. Indeed, adenosine causes tumor-promoting actions and CD73 inhibition increases sensitivity to TMZ in vitro. Here, a cationic nanoemulsion to nasal delivery of siRNA CD73 (NE-siRNA CD73) aiming glioblastoma treatment was employed alone or in combination with TMZ. In vitro, two glioblastoma cell lines (C6 and U138MG) with a chemo-resistant profile were used. Treatment alone with NE-siRNA CD73 reduced C6 and U138MG glioma cell viability by 70% and 25%, respectively. On the other hand, when NE-siRNA + TMZ combined treatment was employed, a reduction of 85% and 33% of cell viability was observed. Notably, treatment with NE-siRNA CD73 of glioma-bearing Wistar rats reduced tumor size by 80%, 60% more than the standard chemotherapy with TMZ, but no synergistic or additive effect was observed in vivo. Additionally, NE-siRNA CD73, TMZ or combined therapy decreased adenosine levels in liquor confirming the importance of this nucleoside on in vivo GB growth. Finally, no hemolytic potential was observed. These results suggest that nasal administration of NE-siRNA CD73 exhibits higher antiglioma effect when compared to TMZ. However, no synergistic or additive in vivo was promoted by the therapeutic regimen employed in this study.

Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical Approach.

Glioblastoma is the most devastating primary brain tumor. Effective therapies are not available, mainly due to high tumor heterogeneity, chemoresistance, and the difficulties imposed by blood-brain barrier. CD73, an enzyme responsible for adenosine (ADO) production, is overexpressed in cancer cells and emerges as a target for glioblastoma treatment. Indeed, ADO causes a variety of tumor-promoting actions, particularly by inducing tumor immune escape, whereas CD73 inhibition impairs tumor progression. Here, a cationic nanoemulsion to deliver CD73siRNA (NE-siRNA CD73R) via nasal route aiming glioblastoma treatment was developed. NE-siRNA CD73R was uptaken by glioma cells in culture, resulting in a parallel 60-80% decrease in AMPase activity and 30-50% in cell viability. Upon nasal delivery, NE-siRNA CD73R was detected in rat brain and serum. Notably, treatment with CD73siRNA complexes of glioma-bearing Wistar rats reduced tumor growth by 60%. Additionally, NE-siRNA CD73R treatment decreased 95% ADO levels in liquor and tumor CD73 expression, confirming in vivo CD73 silencing. Finally, no toxicity was observed in either primary astrocytes or rats with this cationic nanoemulsion. These results suggest that nasal administration of cationic NE as CD73 siRNA delivery system represents a novel potential treatment for glioblastoma. Graphical Abstract Glioblastoma is the most common and devastating form of primary brain tumor. CD73, a protein involved in cell-cell adhesion and migration processes and also responsible for extracellular adenosine (ADO) production, is overexpressed by glioma cells and emerges as an important target for glioma treatment. Indeed, ADO participates in tumor immune escape, cell proliferation, and angiogenesis, and CD73 inhibition impairs those processes. Here, a cationic nanoemulsion to deliver CD73 siRNA (NE-siRNA CD73R) via nasal route aiming glioblastoma treatment was developed. NE-siRNA CD73R knockdown in vitro and in vivo CD73. Upon nasal delivery of NE-siRNA CD73R, the treatment markedly reduced tumor volume by 60% in a rat preclinical glioblastoma model. The treatment was well tolerated, and did not induce kidney, liver, lung, olfactory, bone marrow, or behavior alterations. These results indicate that the nasal administration of NE as a CD73 siRNA delivery system offered an efficient means of gene knockdown and may represent a potential alternative for glioblastoma treatment.

Composição química e repelência de óleos essenciais de Drimys angustifolia Miers e Drimys brasiliensis Miers em cupins de madeira Cryptotermes brevis (Isoptera: Kalotermitidae) / Chemical composition of essential oils of Drimys angustifolia Miers and Drimys brasiliensis Miers and their repellency to drywood termite Cryptotermes brevis (Isoptera: Kalotermitidae)

The essential oils extracted from leaves of the Southern Brazilian native species Drimys angustifolia Miers (DA) and Drimys brasiliensis Miers (DB) by Clevenger distillation were analyzed by gas chromatography/mass spectrometry (GC/MS). The oils of DA and DB consisted predominantly of monoterpenoids and sesquiterpenoids. The largest components of DA oil were bicyclogermacrene (19.6%), sabinene (9.7%)and myrcene (5.2%), while DB oil was characterized by cyclocolorenone (18.2%), followed by terpinen-4-ol (8.7%) and alpha-gurjunene (6.9%). Laboratory tests were carried out to determine the repellency of the essential oils to the drywood termite Cryptotermes brevis (Isoptera: Kalotermitidae). It was observed that the oil showed repellency at the concentrations 25, 12.5, and 6.25 μg/mL. The oils of both species exhibited a negative repellency index, which represents repellent activity, except for DA oil at the highest concentration, which was attractive. Five deaths (11% of the termitesample) were observed at 25 μg/mL DA, in the fourhour repellency test, while four deaths occurred at 12.5 μg/mL (approximately 9%). The essential oil of DB did not cause any termite deaths...

Os óleos essenciais obtidos das folhas das árvores nativas do sul do Brasil Drimys angustifolia Miers (DA)e Drimys brasiliensis Miers (DB) foram analisados por cromatografia gasosa acoplada a espectrometria de massas (CG/EM). O óleo de DA foi caracterizado pela presença de monoterpenóides e sesquiterpenóides, biciclogermacreno (19,6%), seguido por sabineno (9,7%) e mirceno (5,2%). O óleo de DB foi caracterizado por sesquiterpenóides e monoterpenóides, ciclocolorenona (18,2%), seguido por terpinen-4-ol (8,7%) e alfagurjuneno(6,9%). Os testes foram realizados a fim de se determinar o potencial repelente dos óleos essenciais contra o cupim de madeira seca Cryptotermes brevis (Isoptera: Kalotermitidae) nas doses de 25, 12,5, e 6,25 μg/mL. Ambas as espécies mostraram índice de repelência negativo, o que representa a ocorrência da atividade repelente, exceto na maior concentração de DA, na qual o óleo mostrou-se atraente. Cinco mortes foram observadas na concentração de 25 μg/mL de DA, correspondendo a 11% do total em quatro horas de análise, sendo que 9% ocorreram na concentração de 12,5 μg/mL. No caso do óleo essencial de DB não foram observadas mortes de cupins...